Business Context and Reporting Period
Sunshine Biopharma Inc., an emerging growth company incorporated in Colorado, filed this Form 8-K on September 14, 2020. The report details a material definitive agreement entered into on September 8, 2020, with RB Capital Partners, Inc., to secure convertible debt financing.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. The specific financial metrics disclosed relate solely to the new financing arrangement:
- Financing Amount: Minimum of $2 million available over three to six months.
- Initial Funding: $250,000 received on September 14, 2020.
- Interest Rate: 5% per annum.
- Conversion Price: Greater of the market value on the conversion date or $0.30 per share.
- Maturity: Two years from issuance; notes must be fully converted by maturity.
- Prepayment: Allowed at any time without penalty.
Material Changes
The primary material change is the execution of the Financing Agreement with RB Capital Partners, Inc. This represents a new source of capital intended to support the company's operations, distinct from prior periods which are not detailed in this specific filing.
Guidance, Outlook, and Use of Proceeds
Management intends to utilize the proceeds from this financing for the following priorities:
- Development of the company's recently announced Coronavirus treatment.
- Clinical development of Adva-27a, the flagship anticancer compound targeted for pancreatic cancer.
The filing incorporates a press release (Exhibit 99.1) regarding the agreement but does not provide specific forward-looking financial guidance or risk factors beyond the standard terms of the debt instrument.
Investor Verification Checklist
- Verify the total amount of funding actually drawn down against the $2 million minimum commitment.
- Monitor the conversion price relative to the $0.30 floor to assess potential dilution.
- Confirm the progress of the Coronavirus treatment and Adva-27a clinical trials as the primary use of funds.
- Review the full text of the Financing Agreement (Exhibit 10.15) for covenants or conditions not summarized in the 8-K.